MarketPulse

NDV-01

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada's NDV-01 Shows 76% Response Rate, Advancing Bladder Cancer Program

Relmada to present NDV-01 Phase 2 data showing 76% response rate in bladder cancer at AUA 2026 conference; Phase 3 registration trial launches mid-2026.
RLMDclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada Therapeutics to Unveil Q4 2025 Results Amid $160M Funding Boost

Relmada Therapeutics to report Q4 2025 results March 19, 2026, following $160M oversubscribed fundraise and Leerink Partners conference presentation.
RLMDclinical-stage biotechprivate placement